Literature DB >> 18760699

FMRP acts as a key messenger for dopamine modulation in the forebrain.

Hansen Wang1, Long-Jun Wu, Susan S Kim, Frank J S Lee, Bo Gong, Hiroki Toyoda, Ming Ren, Yu-Ze Shang, Hui Xu, Fang Liu, Ming-Gao Zhao, Min Zhuo.   

Abstract

The fragile X mental retardation protein (FMRP) is an RNA-binding protein that controls translational efficiency and regulates synaptic plasticity. Here, we report that FMRP is involved in dopamine (DA) modulation of synaptic potentiation. AMPA glutamate receptor subtype 1 (GluR1) surface expression and phosphorylation in response to D1 receptor stimulation were reduced in cultured Fmr1(-/-) prefrontal cortex (PFC) neurons. Furthermore, D1 receptor signaling was impaired, accompanied by D1 receptor hyperphosphorylation at serine sites and subcellular redistribution of G protein-coupled receptor kinase 2 (GRK2) in both PFC and striatum of Fmr1(-/-) mice. FMRP interacted with GRK2, and pharmacological inhibition of GRK2 rescued D1 receptor signaling in Fmr1(-/-) neurons. Finally, D1 receptor agonist partially rescued hyperactivity and enhanced the motor function of Fmr1(-/-) mice. Our study has identified FMRP as a key messenger for DA modulation in the forebrain and may provide insights into the cellular and molecular mechanisms underlying fragile X syndrome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18760699     DOI: 10.1016/j.neuron.2008.06.027

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  101 in total

1.  Roles of fragile X mental retardation protein in dopaminergic stimulation-induced synapse-associated protein synthesis and subsequent alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-4-propionate (AMPA) receptor internalization.

Authors:  Hansen Wang; Susan S Kim; Min Zhuo
Journal:  J Biol Chem       Date:  2010-05-10       Impact factor: 5.157

Review 2.  GRK2: multiple roles beyond G protein-coupled receptor desensitization.

Authors:  Tama Evron; Tanya L Daigle; Marc G Caron
Journal:  Trends Pharmacol Sci       Date:  2012-01-23       Impact factor: 14.819

Review 3.  Fragile X syndrome and targeted treatment trials.

Authors:  Randi Hagerman; Julie Lauterborn; Jacky Au; Elizabeth Berry-Kravis
Journal:  Results Probl Cell Differ       Date:  2012

4.  Molecular and genetic analysis of the Drosophila model of fragile X syndrome.

Authors:  Charles R Tessier; Kendal Broadie
Journal:  Results Probl Cell Differ       Date:  2012

5.  A 'learning platform' approach to outcome measurement in fragile X syndrome: a preliminary psychometric study.

Authors:  S S Hall; J L Hammond; M Hirt; A L Reiss
Journal:  J Intellect Disabil Res       Date:  2012-04-25

Review 6.  The fragile X mental retardation protein in circadian rhythmicity and memory consolidation.

Authors:  Cheryl L Gatto; Kendal Broadie
Journal:  Mol Neurobiol       Date:  2009-02-12       Impact factor: 5.590

7.  Selective deletion of GRK2 alters psychostimulant-induced behaviors and dopamine neurotransmission.

Authors:  Tanya L Daigle; Mark J Ferris; Raul R Gainetdinov; Tatyana D Sotnikova; Nikhil M Urs; Sara R Jones; Marc G Caron
Journal:  Neuropsychopharmacology       Date:  2014-04-29       Impact factor: 7.853

8.  Fragile X mental retardation protein regulates synaptic and behavioral plasticity to repeated cocaine administration.

Authors:  Laura N Smith; Jakub P Jedynak; Miles R Fontenot; Carly F Hale; Karen C Dietz; Makoto Taniguchi; Feba S Thomas; Benjamin C Zirlin; Shari G Birnbaum; Kimberly M Huber; Mark J Thomas; Christopher W Cowan
Journal:  Neuron       Date:  2014-05-07       Impact factor: 17.173

9.  A Randomized, Double-Blind, Placebo-Controlled Trial of Low-Dose Sertraline in Young Children With Fragile X Syndrome.

Authors:  Laura Greiss Hess; Sarah E Fitzpatrick; Danh V Nguyen; Yanjun Chen; Kimberly N Gaul; Andrea Schneider; Kerrie Lemons Chitwood; Marwa Abd Al Azaim Eldeeb; Jonathan Polussa; David Hessl; Susan Rivera; Randi J Hagerman
Journal:  J Dev Behav Pediatr       Date:  2016-10       Impact factor: 2.225

Review 10.  Fragile X: a family of disorders.

Authors:  Weerasak Chonchaiya; Andrea Schneider; Randi J Hagerman
Journal:  Adv Pediatr       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.